SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
If you or a loved one has recently been diagnosed with hypertrophic cardiomyopathy (HCM), you may have questions about what it means for your health and how to manage the condition. Understanding ...
ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
SONATA-HCM is the only ongoing Phase 3 study in both obstructive and non-obstructive HCM. It is a randomized, double-blind, placebo-controlled multicenter trial that will evaluate the efficacy of ...
Incorporated announced the launch of “On Track with HCM,” demonstrating the company’s long-standing commitment to the, Hypertrophic Cardiomyopathy, HCM community. The campaign features four-time ...
Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases Enrollment underway across U.S. sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results